• Earlier this month, Healthcare Realty Holdings, L.P. entered into a US$400.0 million senior unsecured delayed draw term loan facility maturing in May 2029, with flexible SOFR- or base rate-linked pricing, an accordion option of up to US$100.0 million, and no mandatory amortization.
• The ability to draw this capital over a year, prepay without penalty, and operate under customary covenants highlights lender confidence in Healthcare Realty Trust’s credit profile and balance sheet management.
• We’ll now examine how this new US$400.0 million delayed draw term loan, and its added financial flexibility, could influence Healthcare Realty Trust’s investment narrative.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Healthcare Realty Trust Investment Narrative Recap

To own Healthcare Realty Trust, you need to believe in steady demand for medical office space and the company’s ability to improve operations while managing a still-elevated debt load. The new US$400.0 million delayed draw term loan appears helpful but not transformational in the near term, as the key catalyst remains execution on operational improvements and lease-up, while high leverage and interest costs stay a central risk.

Among recent developments, the reaffirmed 2026 EPS guidance range of -US$0.05 to US$0.05 matters most alongside this facility, because it frames expectations while the company invests in its lease-up portfolio and continues its broader corporate transformation. Taken together, the updated guidance, modest Q1 2026 net loss, and this flexible debt capacity give investors a clearer line of sight on how Healthcare Realty plans to balance reinvestment, deleveraging, and earnings stabilization.

However, investors should be aware that if higher leverage combines with any setback in asset sales or refinancing plans, the company’s interest burden could...

Healthcare Realty Trust's narrative projects $1.2 billion revenue and $220.9 million earnings by 2029. This requires 1.0% yearly revenue growth and a $424.7 million earnings increase from -$203.8 million today.

Uncover how Healthcare Realty Trust's forecasts yield a $20.45 fair value, in line with its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$20.45 to US$27.56 per share, reflecting very different views on upside. You can weigh those against the current emphasis on balance sheet flexibility and operational execution as key drivers of Healthcare Realty Trust’s future performance, and explore how other community members are thinking about these trade offs.

Explore 2 other fair value estimates on Healthcare Realty Trust - why the stock might be worth as much as 37% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Healthcare Realty Trust research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Healthcare Realty Trust research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Healthcare Realty Trust's overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.